SUPN Insider Trading

Insider Ownership Percentage: 9.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $7,048,693.06

Supernus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Supernus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$440ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Supernus Pharmaceuticals Share Price & Price History

Current Price: $31.26
Price Change: Price Increase of +0.09 (0.29%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for SUPN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$31.26Closing price on 03/14/25:

SEC Filings (Institutional Ownership Changes) for Supernus Pharmaceuticals (NASDAQ:SUPN)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SUPN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$89Mbought$70MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Supernus Pharmaceuticals logo
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Read More on Supernus Pharmaceuticals

Today's Range

Now: $31.26
Low: $31.11
High: $31.57

50 Day Range

MA: $36.22
Low: $31.17
High: $40.00

52 Week Range

Now: $31.26
Low: $25.53
High: $40.28

Volume

526,106 shs

Average Volume

564,157 shs

Market Capitalization

$1.74 billion

P/E Ratio

29.22

Dividend Yield

N/A

Beta

0.83

Who are the company insiders with the largest holdings of Supernus Pharmaceuticals?

Supernus Pharmaceuticals' top insider investors include:
  1. Jack A Khattar (CEO)
  2. Tami Tillotson Martin (VP)
  3. Frederick M Hudson (Director)
  4. Georges Gemayel (Director)
  5. Padmanabh P Bhatt (VP)
  6. Frank Mottola (SVP)
  7. Jonathan Rubin (SVP)
Learn More about top insider investors at Supernus Pharmaceuticals.

Who are the major institutional investors of Supernus Pharmaceuticals?

Supernus Pharmaceuticals' top institutional investors include:
  1. Vanguard Group Inc. — 11.14%
  2. Dimensional Fund Advisors LP — 5.21%
  3. Stephens Investment Management Group LLC — 3.17%
  4. Polar Capital Holdings Plc — 3.06%
  5. Renaissance Technologies LLC — 2.90%
  6. Pacer Advisors Inc. — 2.89%
Learn More about top institutional investors of Supernus Pharmaceuticals stock.

Which major investors are selling Supernus Pharmaceuticals stock?

In the last quarter, SUPN stock was sold by these institutional investors:
  1. Polar Capital Holdings Plc
  2. Millennium Management LLC
  3. Schroder Investment Management Group
  4. Stephens Investment Management Group LLC
  5. Pacer Advisors Inc.
  6. Renaissance Technologies LLC
  7. Aristotle Capital Boston LLC
  8. Voloridge Investment Management LLC
Within the last year, company insiders that have sold Supernus Pharmaceuticals company stock include:
  1. Jack A Khattar (CEO)
  2. Tami Tillotson Martin (VP)
  3. Frederick M Hudson (Director)
  4. Georges Gemayel (Director)
  5. Padmanabh P Bhatt (VP)
Learn More investors selling Supernus Pharmaceuticals stock.

Which major investors are buying Supernus Pharmaceuticals stock?

In the last quarter, SUPN stock was bought by institutional investors including:
  1. Woodline Partners LP
  2. BNP Paribas Financial Markets
  3. Raymond James Financial Inc.
  4. Raymond James Financial Inc.
  5. Great Lakes Advisors LLC
  6. D. E. Shaw & Co. Inc.
  7. Cubist Systematic Strategies LLC
  8. Norges Bank